Jaguar Health, Inc. (JAGX): Total Liabilities
$57.01M
As of 2025-12-31
$29.27M
As of 2026-06-30
+5.3%
3-year compound annual growth
+17.3%
5-year compound annual growth
+21.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $57.01M | +28.3% | 2026-04-07, Balance as of period end |
| 2024-12-31 | $44.45M | -3.1% | 2026-04-07, Balance as of period end |
| 2023-12-31 | $45.87M | -6.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $48.81M | +17.9% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $41.41M | +61.5% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $25.64M | +61.9% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $15.84M | -40.6% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $26.66M | +1.1% | 2020-04-03, Balance as of period end |
| 2017-12-31 | $26.37M | +338.2% | 2019-04-10, Balance as of period end |
| 2016-12-31 | $6.02M | -24.8% | 2018-04-09, Balance as of period end |
| 2015-12-31 | $8.01M | +49.6% | 2017-02-15, Balance as of period end |
| 2014-12-31 | $5.35M | n/a | 2016-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $57.01M | +28.3% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $37.28M | -20.8% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $19.38M | -32.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $32.02M | +37.2% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $44.74M | +15.5% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $141.50M | +146.0% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $134.59M | +71.4% |
Compare JAGX, PRLD, CBIO, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗